<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00072410</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000339682</org_study_id>
    <secondary_id>MSKCC-03069</secondary_id>
    <secondary_id>LUDWIG-LUD01-018</secondary_id>
    <nct_id>NCT00072410</nct_id>
  </id_info>
  <brief_title>Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer</brief_title>
  <official_title>Single-Dose, Cohort Study of Increasing Doses of Yttrium-90 Conjugated to Humanized Monoclonal Antibody 3S193 (90Y-hu3S193) in Patients With Advanced Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig Institute for Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig Institute for Cancer Research</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radioactive&#xD;
      tumor-killing substances to them without harming normal cells. Giving radiolabeled monoclonal&#xD;
      antibody directly into the abdominal cavity may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of giving radiolabeled monoclonal antibody&#xD;
      therapy directly into the abdominal cavity in treating patients who have advanced ovarian&#xD;
      epithelial cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety and maximum tolerated dose of intraperitoneal yttrium Y 90&#xD;
           monoclonal antibody Hu3S193 (Y90 MOAB Hu3S193) in patients with advanced ovarian&#xD;
           epithelial cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the localization and whole body and abdominal clearance of this drug in these&#xD;
           patients using indium In 111 monoclonal antibody Hu3S193 and gamma camera imaging.&#xD;
&#xD;
        -  Determine the serum pharmacokinetics of Y90 MOAB Hu3S193 in these patients using gamma&#xD;
           well counting.&#xD;
&#xD;
        -  Determine the antibody response in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of yttrium Y 90 monoclonal antibody Hu3S193 (Y90&#xD;
      MOAB Hu3S193).&#xD;
&#xD;
      Patients receive intraperitoneal (IP) technetium Tc 99m sulfur colloid and undergo abdominal&#xD;
      imaging on day 1. Provided distribution of technetium Tc 99m sulfur colloid is deemed&#xD;
      adequate, patients then receive IP Y90 MOAB Hu3S193 and IP indium In 111 monoclonal antibody&#xD;
      Hu3S193 (for imaging) over 30 minutes on day 1. Within 3-5 hours after antibody&#xD;
      administration, patients undergo whole body imaging and single-photon emission-computed&#xD;
      tomography (SPECT) imaging of the abdomen and pelvis.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of Y90 MOAB Hu3S193 until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for at least 2 years and then every 6 months for up to 5&#xD;
      years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 42 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>yttrium Y 90 monoclonal antibody Hu3S193</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed non-mucinous ovarian adenocarcinoma&#xD;
&#xD;
          -  Persistent or recurrent intraperitoneal disease after platinum/taxane-based therapy&#xD;
             for stage III ovarian cancer&#xD;
&#xD;
          -  No active parenchymal disease (stage IV)&#xD;
&#xD;
          -  No symptomatic extraabdominal metastases&#xD;
&#xD;
          -  No known CNS tumor involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  No bleeding disorders&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF at least 50%&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No clinically significant arrhythmia by ECG&#xD;
&#xD;
          -  No evidence of prior myocardial infarction&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  FEV_1 at least 60% of predicted&#xD;
&#xD;
          -  FVC at least 60% of predicted&#xD;
&#xD;
          -  Diffusion capacity at least 55% of predicted&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No other serious illness that would preclude study participation&#xD;
&#xD;
          -  No serious infection requiring antibiotics&#xD;
&#xD;
          -  No chronic inflammatory bowel disease&#xD;
&#xD;
          -  Human antimouse antibody negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy&#xD;
&#xD;
          -  No prior murine monoclonal antibody therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No immunosuppressive therapy for 30 days after the administration of yttrium Y 90&#xD;
             monoclonal antibody Hu3S193&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chaitanya R. Divgi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 4, 2003</study_first_submitted>
  <study_first_submitted_qc>November 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2003</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

